Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study. Which dose of CagriSema participants will continue on is decided by chance. If participants get placebo in the main study, participants will get CagriSema in the extension study. Participants will take one injection of study medicine once a week. The study will last for about 3 years and 3 months.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
FDRC
Costa Mesa, California, United States
Linda Vista Health Care Ctr
San Diego, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Northeast Research Institute
Fleming Island, Florida, United States
Jacksonville Ctr For Clin Res
Jacksonville, Florida, United States
South Broward Research LLC
Miramar, Florida, United States
Florida Inst For Clin Res LLC
Orlando, Florida, United States
Oviedo Medical Research, LLC
Oviedo, Florida, United States
Cnt for Diab,Obes, and Metab
Pembroke Pines, Florida, United States
Hope Clin Res & Wellness
Conyers, Georgia, United States
Start Date
June 3, 2025
Primary Completion Date
March 1, 2027
Completion Date
October 17, 2028
Last Updated
December 12, 2025
609
ACTUAL participants
CagriSema (Cagrilintide B and Semaglutide I)
DRUG
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
DRUG
Lead Sponsor
Novo Nordisk A/S
NCT01143454
NCT07472881
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions